Cargando…
Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation
Radiofrequency ablation (RFA) is an important strategy for treatment of advanced hepatocellular carcinoma (HCC). However, the prognostic indicators of RFA therapy are not known, and there are few strategies for RFA sensitization. The transcription factor sterol regulatory element binding protein 1 (...
Autores principales: | Zou, Xiao-zheng, Hao, Jun-feng, Zhou, Xiu-hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660695/ https://www.ncbi.nlm.nih.gov/pubmed/34900747 http://dx.doi.org/10.3389/fonc.2021.796152 |
Ejemplares similares
-
Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research
por: Wu, Shilun, et al.
Publicado: (2022) -
SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway: SREBP2 Inhibitor sensitizes HCC to lenvatinib
por: Fan, Minghao, et al.
Publicado: (2023) -
A Radiomics Nomogram for Preoperative Prediction of Early Recurrence of Small Hepatocellular Carcinoma After Surgical Resection or Radiofrequency Ablation
por: Wen, Liting, et al.
Publicado: (2021) -
Multiple-Electrode Switching-Based Radiofrequency Ablation vs. Conventional Radiofrequency Ablation for Single Early-Stage Hepatocellular Carcinoma Ranging From 2 to 5 Cm
por: Huang, Guang-liang, et al.
Publicado: (2020) -
Recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors
por: Chen, Rui, et al.
Publicado: (2023)